Intended for US audiences only
DANYELZA® (naxitamab-gqgk) is available at treatment centers across the United States. See below to find the treatment center nearest to you with experience administering DANYELZA. Please note that the treatment centers listed here are only those that have authorized their participation on our website. Please check back regularly as this list will be updated periodically.
*The contact information for these treatment centers is provided as a courtesy, and it is not intended as an endorsement or recommendation of any healthcare provider/treatment center. Y-mAbs Therapeutics does not make any representations or guarantees about the qualifications, competence, or skills of any healthcare provider/treatment center, the accuracy of any diagnosis, or the appropriateness of any treatment that a healthcare provider may prescribe or recommend. Patients should make their own, independent decisions regarding the capabilities and suitability of potential healthcare providers/treatment centers, and
Y-mAbs does not play a role in any patient-provider relationship you may establish.
What is the most important information I should know about DANYELZA?
DANYELZA may cause serious side effects, including:
DANYELZA is a prescription medicine used in combination with a medicine called granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat children 1-year of age and older and adults with high-risk neuroblastoma in the bone or bone marrow that:
DANYELZA is approved based on two clinical studies that looked at reducing tumor size. DANYELZA is still being studied to confirm the study results and the clinical benefit of treatment.
What is the most important information I should know about DANYELZA?
DANYELZA may cause serious side effects, including:
DANYELZA is a prescription medicine used in combination with a medicine called granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat children 1-year of age and older and adults with high-risk neuroblastoma in the bone or bone marrow that:
DANYELZA is approved based on two clinical studies that looked at reducing tumor size. DANYELZA is still being studied to confirm the study results and the clinical benefit of treatment.